Zdrowie i gospodarka · 07/10/2014

FDA Releases Guidance on Pathological Complete Response for High-Risk Breast Cancer Treatment

The FDA has released a guidance document to help pharmaceutical companies design clinical trials for breast cancer treatments using pathological complete response as a key endpoint, aiming to accelerate the development of new therapies for high-risk patients.